{"data":{"ModuleTitle":{"label":"Module Title","value":"Company Description"},"CompanyName":{"label":"Company Name","value":"Omega Therapeutics, Inc."},"Symbol":{"label":"Symbol","value":"OMGA"},"Address":{"label":"Address","value":"20 ACORN PARK DRIVE, CAMBRIDGE, Massachusetts, 02140, United States"},"Phone":{"label":"Phone","value":"+1 617 949-4360"},"Industry":{"label":"Industry","value":"Biotechnology: Biological Products (No Diagnostic Substances)"},"Sector":{"label":"Sector","value":"Health Care"},"Region":{"label":"Region","value":"North America"},"CompanyDescription":{"label":"Company Description","value":"Omega Therapeutics Inc is a development-stage biotechnology company leveraging its proprietary epigenomic programming platform to biologically engineer a new class of programmable epigenetic medicines, known as Omega Epigenomic Controllers. Using the epigenomic controllers, Omega is seeking to transform the practice of human medicine through highly selective and direct control of the human genome to treat and cure disease."},"CompanyUrl":{"label":"Company Url","value":"https://www.omegatherapeutics.com"},"KeyExecutives":{"label":"Key Executives","value":[{"name":"Jennifer Nelson","title":"Chief Scientific Officer"},{"name":"Kaan Certel","title":"President, Chief Executive Officer & Director"},{"name":"Samir Padalkar","title":"Vice President-Data & IT"}]}},"message":null,"status":{"rCode":200,"bCodeMessage":null,"developerMessage":null}}